BMJ  2008;336:56-57 (12 January), doi:10.1136/bmj.39454.496748.80

Editorials

Parliamentary review asks NICE to do better still

Out goes the arbitrary funding threshold: in come NICE "directives"

The first 150 words of the full text of this article appear below.

On Wednesday 9 January 2008, the House of Commons health select committee published the report of its second inquiry into the National Institute for Health and Clinical Excellence (NICE).¹ The committee’s first inquiry into NICE was published six years ago,² just three years after the institute’s launch. Much has happened since the initial inquiry. The institute is now well established and is a core policy driver within the National Health Service in England and Wales (its remit does not cover Scotland), and we know much more about how it operates. Moreover, the working environment of the institute has changed with, for instance, the publication of the Cooksey report on funding for health research in the United Kingdom,³ the introduction of legislation making NICE technology appraisals essentially compulsory,⁴ the involvement of the courts in a legal challenge to NICE,⁵ and most recently the Office of Fair Trading’s critical review of how . . . [Full text of this article]

¹ St George’s Hospital, University of London, SW17 0RE

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Related Article

Value based pricing for NHS drugs: an opportunity not to be missed?

Karl Claxton, Andrew Briggs, Martin J Buxton, Anthony J Culyer, Christopher McCabe, Simon Walker, and Mark J Sculpher
BMJ 2008 336: 251-254. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Claxton, K., Briggs, A., Buxton, M. J, Culyer, A. J, McCabe, C., Walker, S., Sculpher, M. J (2008). Value based pricing for NHS drugs: an opportunity not to be missed?. BMJ 336: 251-254 [Full text]